正文
《医学前沿(英文)》 >> 2020年 第14卷 第6期 doi: 10.1007/s11684-020-0740-6
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
. Department of Hematology, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Department of Imaging, Tongji Hospital of Tongji University School of Medicine, Shanghai 200065, China.. Clinical Translational Research Center, Shanghai Pulmonary Hospital of Tongji University School of Medicine, Shanghai 200433, China
摘要
关键词
anti-CD19 chimeric antigen receptor T cells ; mantle cell lymphoma ; relapsed or refractory ; long-term follow-up
正文